Duloxetine Capsule, Delayed Release
Product Images NDC 68788-8608

17 FDA label images from Preferred Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-8608). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)
Chemical structure diagram of Duloxetine hydrochloride, showing its molecular arrangement with a naphthyl group, thiophene ring, and a methylamino side chain with an HCl component.*
FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)
A Kaplan-Meier estimator method graph depicting the proportion of patients with relapse over time (days) from randomization. The plot compares two treatments: placebo (dashed line) and duloxetine (solid line), showing the relapse rates on the y-axis against days on the x-axis up to 200 days.*
FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)
A Kaplan-Meier curve comparing the proportion of patients with relapse over time in days from randomization, for Duloxetine and placebo groups. The x-axis shows time (days), and the y-axis shows the proportion of patients with relapse, with Duloxetine having a lower relapse proportion than placebo throughout the observation period.*
FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)
A line graph showing the percentage of patients improved against percent improvement in pain from baseline. Four groups are compared: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph illustrates how patient improvement varies with increasing percent pain improvement thresholds.*
FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)
A line graph comparing percentage improvement in pain from baseline against the percentage of patients improved. It includes three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved, with both Duloxetine groups showing higher improvement than placebo across the range.*
FDA Label Image

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)
A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. Three lines represent Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing a decreasing trend in patient improvement as the percent improvement threshold increases.*
FDA Label Image

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)
A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline for Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two different data series), and placebo. The y-axis represents the percentage of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100%.*
FDA Label Image

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)
A line graph titled 'Percentage of Pediatric Patients Aged 13 to 17 Years old with Juvenile Fibromyalgia Syndrome Achieving Various Levels of Pain Relief at week 12 (Study FM-4)' showing pain improvement percentages on the x-axis and percentage of patients improved on the y-axis. It compares duloxetine 60 mg once daily to placebo, illustrating higher percentages of patients showing pain relief with duloxetine across various improvement thresholds.*
FDA Label Image

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)
A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines represent placebo (marked by x) and Duloxetine (marked by diamonds) with Duloxetine consistently showing higher patient improvement across improvement percentages.*
FDA Label Image

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo groups. The x-axis shows increasing percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher patient improvement percentages relative to placebo across the improvement scale.*
FDA Label Image

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The graph includes two lines: one for placebo marked with crosses and one for Duloxetine 60/120 mg once daily marked with diamonds. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved.*
FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)
Duloxetine 30 mg delayed-release capsules packaging label. The label is predominantly white with a dark blue and black design of stylized flowers or shapes arranged vertically down the center. The label includes the proprietary name Duloxetine and indicates the capsule dosage form and strength. The labeler is Preferred Pharmaceuticals Inc.*
FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)
Duloxetine 30 mg delayed-release capsules in a blister pack, with 10 capsules visible. The packaging shows the capsules with distinctive markings. Labeler is Preferred Pharmaceuticals Inc.*
FDA Label Image

20mg-60s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 12)

20mg-60s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 12)
The label for Duloxetine Delayed-Release Capsules, USP 20 mg, showing it is manufactured by Lupin Pharmaceuticals, Inc. and Lupin Limited in India. The label includes the NDC 68180-294-07 and states pharmacist instructions to dispense the medication guide to each patient. The package contains 60 capsules with Rx only designation and storage instructions.*
FDA Label Image

30mg-30s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 13)

30mg-30s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 13)
Label for Duloxetine Delayed-Release Capsules USP 30 mg, oral capsules. The label includes dosage information, storage conditions, and manufacturer details for Lupin Pharmaceuticals. The package contains 30 capsules and includes barcode and QR code for medication guide access.*
FDA Label Image

40mg-30s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 14)

40mg-30s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 14)
Label for Duloxetine delayed-release capsules, USP 40 mg, oral dosage form. The label indicates 30 capsules per container, labeled for prescription use only by Lupin Pharmaceuticals, Inc. It includes storage instructions, a medication guide reference, and manufacturing details by Lupin Limited in India. The label also features the NDC 68180-297-06 and a barcode.*
FDA Label Image

60mg-30s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 15)

60mg-30s (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 15)
Packaging label for Duloxetine Delayed-Release Capsules, USP, 60 mg strength. The label indicates the product contains 30 capsules and is distributed by Lupin Pharmaceuticals, Inc. The label includes storage instructions and a QR code for the medication guide. The dosage form is delayed-release capsules for oral use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.